← Leaderboards
Krishna V. Komanduri
University Of Texas Md Anderson Can Ctr
$2,441,315
Attributed
$3,949,140
Total exposure
3
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $671.1K · FY2005–23$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$3,949,140 · 3
By mechanism
R01$2,878,215 · 2
UG1$1,070,925 · 1
Top collaborators
- Asad Bashey7 shared
- Edward A. Copelan7 shared
- Paul Szabolcs4 shared
Most similar at University Of Texas Md Anderson Can Ctr
Same institution · by research overlap
- Jeffrey J Molldrem$7,910,420
- Sergio A. Giralt$6,224,032
- Richard E. Champlin$5,988,814
- Donald A Berry$14,634,533
- Beverly R Raney$359,798
Others in their field
Top investigators on “Allogenic”
- Gautam (george) Mitra · Leidos Biomedical Research, Inc.$53,523,213
- Mary M Horowitz · Medical College Of Wisconsin$47,632,939
- Hans-Peter Kiem · Fred Hutchinson Cancer Center$40,815,122
- Marcel R M Van Den Brink · Sloan-Kettering Institute For Cancer Res$39,678,762
- Bruce R. Blazar · University Of Minnesota$37,193,531
- Megan Sykes · Columbia University Health Sciences$33,587,479
Research focus
AllogenicConditioningMorbidity - Disease RateSiblingsFutureChronic Graft Versus Host DiseaseFamilyDesignRelapseTransplantationLymphoidRegimenHematopoieticNatural Killer CellsBaseRecoveryAntigensProductionReconstitutionRecovery Of FunctionMemoryInfectionPeripheralMortality Vital Statistics
Grant awards (16)
Reduction of Relapse Risk Through Incorporation of Novel Biologic Agents Following Reduced Intensity Haploidentical Donor Transplant for Acute Myeloid Leukemia.$152,051
UG1 · FY2023 · HL
Reduction of Relapse Risk Through Incorporation of Novel Biologic Agents Following Reduced Intensity Haploidentical Donor Transplant for Acute Myeloid Leukemia.$153,075
UG1 · FY2022 · HL
Reduction of Relapse Risk Through Incorporation of Novel Biologic Agents Following Reduced Intensity Haploidentical Donor Transplant for Acute Myeloid Leukemia.$154,100
UG1 · FY2021 · HL
Reduction of Relapse Risk Through Incorporation of Novel Biologic Agents Following Reduced Intensity Haploidentical Donor Transplant for Acute Myeloid Leukemia.$155,199
UG1 · FY2020 · HL
Reduction of Relapse Risk Through Incorporation of Novel Biologic Agents Following Reduced Intensity Haploidentical Donor Transplant for Acute Myeloid Leukemia.$156,263
UG1 · FY2019 · HL
Reduction of Relapse Risk Through Incorporation of Novel Biologic Agents Following Reduced Intensity Haploidentical Donor Transplant for Acute Myeloid Leukemia.$149,563
UG1 · FY2018 · HL
Reduction of Relapse Risk Through Incorporation of Novel Biologic Agents Following Reduced Intensity Haploidentical Donor Transplant for Acute Myeloid Leukemia.$150,674
UG1 · FY2017 · HL
Immune Reconstitution After Cord Blood Transplantation$386,750
R01 · FY2011 · HL · contact PI
Immune Reconstitution After Cord Blood Transplantation$386,750
R01 · FY2010 · HL · contact PI
Immune Reconstitution After Cord Blood Transplantation$413,250
R01 · FY2009 · HL · contact PI
T Cell Reconstitution After Allogeneic SCT$257,865
R01 · FY2009 · CA · contact PI
Immune Reconstitution After Cord Blood Transplantation$401,000
R01 · FY2008 · HL · contact PI
T Cell Reconstitution After Allogeneic SCT$252,808
R01 · FY2008 · CA · contact PI
T Cell Reconstitution After Allogeneic SCT$252,808
R01 · FY2007 · CA · contact PI
T Cell Reconstitution After Allogeneic SCT$260,359
R01 · FY2006 · CA · contact PI
T Cell Reconstitution After Allogeneic SCT$266,625
R01 · FY2005 · CA